Skip to main content

Table 1 Frozen lung Cohort: Demographic and clinical characteristics and ADAM15 gene expression levels

From: ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction

Characteristics Non-smokersa (N = 17) Smokersa (N = 30) COPD GOLD stages I-II (N = 31) COPD GOLD stages III-IV (N = 17) P valuec
Number of males (%) 12 (70) 20 (67) 22 (70) 12 (70) NS
Age (years) 45 (20–77) 62 (25–78) 67 (50–81) 60 (49–73) P ≤ 0.02d
Pack-yrs. of smoking 0 41 (15–80) 53 (20–100) 58 (10–114) P ≤ 0.03e
Number of current smokers (%) 0 (0) 13 (43) 18 (58) 3 (18) P ≤ 0.02f
FEV1(% of predicted)b 93 (79–104) 94 (65–115) 75 (51–118) 29 (10–48) P ≤ 0.008g
FEV1/FVC (% of predicted)b 80 (73–84) 78 (71–89) 61 (47–68) 43 (25–60) P < 0.001h
ADAM15mRNA Levels in Lungs 1 ± 0.6 0.84 ± 0.6 0.82 ± 0.5 2 ± 0.8 P = 0.001i
  1. The table shows the demographic and clinical characteristics of the patients with COPD, smokers without COPD, and non-smoker controls from whom lung tissue was obtained following lung volume reduction surgery, lung transplantation, a lobectomy, or a lung biopsy. Patients with COPD were sub-divided according to Global Initiative for Obstructive Lung Disease (GOLD) criteria. Total RNA was isolated from the lung samples, and ADAM15 steady-state mRNA levels were quantified using a quantitative real-time reverse transcription PCR assay
  2. Data are presented as median (interquartile range) for data that were not normally distributed or mean ± SD for data that were normally distributed
  3. a Non-smokers were all never-smokers. Smokers were defined as subjects who had a > 10 pack-years smoking history. Current smokers were defined as active smokers at the time the sample was obtained, or those who had stopped smoking < 1 year before the sample was obtained
  4. b All patients with COPD had forced expiratory volume in 1 s/forced vital capacity ratio (FEV1/FVC) < 0.7, whereas smokers without COPD and non-smoker controls had FEV1/FCV > 0.7
  5. c Categorical variables were analyzed with z-tests. Statistical analyses included One-Way ANOVA tests for continuous variables (age, FEV1% predicted, FEV1/FCV, and pack-years of smoking history) followed by pair-wise comparisons using 2 tailed Student’s t-tests for parametric data or Mann-Whitney U tests for non-parametric data
  6. d The non-smokers were significantly younger than the smokers, and the GOLD stage I-II and GOLD stage III-IV patients with COPD (P = 0.003, P < 0.001, and P = 0.02, respectively). There were no significant differences between the ages among the smoker, GOLD stage I-II patients with COPD, and GOLD stage III-IV patients with COPD groups
  7. e The pack-years of smoking histories of the GOLD stage I-II and GOLD stage III-IV COPD groups and the smoker group were significantly different from those of the non-smoker group by design (P < 0.001 for both comparisons). The pack-years of smoking histories of the smoker group were significantly different from those of the GOLD stage I-II and GOLD stage III-IV COPD groups (P = 0.005 and P = 0.03, respectively). The pack-years of smoking histories of GOLD stage I-II COPD group were not significantly different from those of the GOLD stage III-IV COPD group (P = 0.98)
  8. f The proportion of current smokers in the COPD GOLD stage III-IV group was significantly different from that of the GOLD stage I-II group (P = 0.02), but not the non-smoker or smoker groups (P = 0.2 and P = 0.16, respectively). The proportion of current smokers in the COPD GOLD stage I-II was significantly different from that of the non-smoker group (P < 0.001) but not the smoker group (P = 0.4). The proportion of current smokers in the smoker group was significantly different from that of the non-smoker group (P = 0.005)
  9. g The FEV1 values for the GOLD stage III-IV COPD group were significantly lower than those of the non-smoker, smoker, and GOLD stage I-II COPD groups (P < 0.001 for all comparisons). The FEV1 values for the GOLD stage I-II COPD group were significantly lower than those of the non-smoker and smoker groups (P = 0.008 and P < 0.001, respectively)
  10. h The FEV1/FVC ratios for the GOLD stage III-IV patients with COPD were significantly lower than those for the non-smoker, smoker, and GOLD stage I-II COPD groups (P < 0.001 for all comparisons). The FEV1/FVC ratios for the GOLD stage I-II patients with COPD were significantly lower than those for the non-smoker and smoker groups (P < 0.001 for both comparisons)
  11. iADAM15 steady state mRNA levels in human lung samples expressed as fold change relative to the non-smoker control data. P values were adjusted to correct for differences in sex, age, pack-years of smoking history, and current smoker status between the patients with COPD and controls using an ordinal logistic regression model. After adjusting for these covariates, ADAM15 mRNA levels in lungs samples from the patients with COPD with GOLD stage III-IV disease remained significantly higher than those in lung samples from the non-smokers, smokers, and COPD patients with GOLD stage I-II disease. The adjusted P value is shown in the table. ADAM15 mRNA levels in lung samples from patients with COPD with GOLD stage I-II disease were not significantly different from those in the non-smoker and smoker samples
  12. NS not significant